Compare Plby Group Inc (PLBY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Sanofi SA — how do they compare? Plby Group Inc trades at $0.98 (market cap $118.21M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 805.2× Plby Group Inc's market cap, and Sanofi SA pays a 6.01% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Sanofi SA for 94 Days on average.
| PLBY | SNY | |
|---|---|---|
Market Cap | $118.21M | $95.18B |
Volume | 919,783 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $52.34 |
52-Week Low | $0.99 | $39.51 |
Typical Hold Time | 24 Days | 94 Days |
Enterprise Value | $263.80M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $0.9867, down 3.26% today, amid bearish technical signals but with improving fundamentals. Recent earnings show a Q2 2026 beat, and cash flow turned positive in 2025. The company is expanding leadership to drive growth, yet faces high debt and negative equity. Analyst consensus is 75% buy, reflecting optimism on turnaround efforts.
Outlook hinges on execution of growth initiatives and debt management. Opportunities include brand licensing expansion and media strategy, but risks from high leverage and competitive pressures persist. Investors should weigh improving operational trends against financial stability concerns.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
